Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adolescents between and including 11-17 years of age, who provide written informed consent~Exclusion Criteria:~* Subjects with a previous or suspected disease caused by N. meningitidis; or previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s); Any serious acute, chronic or progressive disease

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 17 Years
- Healthy Volunteers: None

Study Arms:
- MenACWY-CRM(Ad+) (Type: EXPERIMENTAL): Subjects received one single dose of adjuvanted formulation of conjugate vaccine.
- MenACWY-CRM(Ad-) (Type: EXPERIMENTAL): Subjects received one single dose of unadjuvanted formulation of conjugate vaccine.
- MenACWY- PS (Type: ACTIVE_COMPARATOR): Subjects received one single dose of the polysaccharide vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).